Engineered Bacterial Strains for Antibiotic Resistance Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for testing antibiotics are inefficient in identifying specific mechanisms of antibiotic resistance, making it difficult to develop effective antimicrobial agents against drug-resistant bacteria like Klebsiella pneumoniae and Escherichia coli, which are major clinical threats due to their complex resistance mechanisms.
Innovation Solution
A platform technology using genetically engineered bacterial strains with identified resistance mechanisms, allowing for the evaluation and screening of antimicrobial agents by comparing their activity against wild-type and engineered strains with specific resistance traits, thereby identifying agents effective against particular resistance mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If clinical drug-resistance isolates are collected and used for testing and screening antibiotics, then a large number of isolates can be tested, but the resistance mechanisms in clinical isolates are complex and not fully identified, making it difficult to verify which mechanism is actually involved
Solution Approach 1:
The patent segments the complex resistance mechanisms into distinct, individually engineered components. Instead of testing against whole clinical isolates with multiple overlapping resistance mechanisms, the invention creates separate bacterial strains each engineered to express a specific resistance mechanism (e.g., efflux pumps, beta-lactamases, target modifications). This segmentation allows clear identification of which specific mechanism confers resistance to which antibiotic, resolving the information loss problem while maintaining high-throughput screening capability.
2Measurement precision
If genetically engineered strains with identified resistance mechanisms are used, then specific resistance mechanisms can be identified efficiently, but the system requires genetic engineering processes
Solution Approach 1:
The patent creates simplified copies of clinical resistance mechanisms through genetic engineering. Rather than working with the complex original clinical isolates, the invention engineers bacterial strains that copy and express individual resistance mechanisms in isolation. These engineered strains serve as standardized models that replicate the essential resistance properties without the confounding complexity of natural clinical isolates, enabling precise mechanism identification through relatively straightforward genetic manipulation.
3Productivity
If conventional screening methods using clinical resistant isolates are used, then screening can be performed, but it is labor intensive and not workable for large-scale screening
Solution Approach 1:
The patent creates a universal platform of engineered bacterial strains that can be used for screening multiple antibiotics and multiple resistance mechanisms simultaneously. The core wild-type strain serves as a universal parent that can generate various engineered variants expressing different resistance mechanisms. This universal system allows high-throughput screening across many compounds and mechanisms without the labor-intensive process of individually characterizing each clinical isolate, enabling large-scale screening with reduced operational complexity.
Data Source
AI summary
The present invention provides a platform technology for testing, screening, selecting and evaluating antibiotics by using genetically engineered strains with identified, individual or combined, resistance mechanisms, prepared from fully susceptible clinical isolates. This antibiotic testing and screening system of the present invention can efficiently and effectively evaluate antibiotics against specified resistance mechanisms in vitro and in vivo, and is suitable on the novel antibiotic development in against multidrug-resistant bacteria.